Loading
A phase 2 trial of Artesunate vaginal insert in vaginal cancer, run by Frantz Viral Therapeutics, LLC, now recruiting.
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3) is a phase 2 interventional study registered as NCT04098744 by Frantz Viral Therapeutics, LLC, with 78 participants planned, started 2020-09-09 and due to reach its primary completion in 2026-07-31. Interventions recorded: Artesunate vaginal insert and Placebo vaginal insert.
Shares Frantz Viral Therapeutics and the tag pipeline.
Shares Vaginal cancer and the tag pipeline.
Shares Vaginal cancer and the tag pipeline.
Shares Frantz Viral Therapeutics, Vaginal cancer.